top border
top border
Featured Program
Targeted therapies in non-small cell lung cancer include EGFR inhibitors and ALK inhibitors. Gregory J. Riely, MD, Alice Shaw, MD, PhD, Mark Socinski, MD, provide insight into the latest research in advanced non-small cell lung cancer, including next-generation agents and novel treatment approaches. View Now

The ever increasing landscape of therapeutic choices available for lung adenocarcinoma adds complexity when determining the best approach for treatment. This OncLive Peer Exchange moderated by Mark Socinski, MD, focuses on what to consider when choosing a treatment strategy for an individual patient. The panelists are Benjamin Levy, MD; John Longshore, PhD; Gregory Riely, MD, PhD; Thomas Stinchcombe, MD; and Jared Weiss, MD. View Now
Featured Video

Hepatocellular Carcinoma (HCC):
Can We Improve Patient Survival?

Hepatocellular Carcinoma (HCC): Can We Improve Patient Survival?
Richard Finn, MD, Laura M. Kulik, MD, and Matthew S. Johnson, MD, FSIR, discuss the evolving systemic treatment paradigm for patients with advanced hepatocellular carcinoma. View now

Gina Columbus

Gina Columbus reports on the latest news in oncology in this week's edition of OncLive News Network.

Publication Bottom Border
Border Publication